期刊
CURRENT OPINION IN CELL BIOLOGY
卷 20, 期 2, 页码 242-248出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/j.ceb.2008.01.002
关键词
-
类别
资金
- Cancer Research UK Funding Source: Medline
- NCI NIH HHS [R01 CA030721-05, R01 CA030721] Funding Source: Medline
ROCK kinases, which play central roles in the organization of the actin cytoskeleton, are tantalizing targets for the treatment of human diseases. Deletion of ROCK I in mice revealed a role in the pathophysiological responses to high blood pressure, and validated ROCK inhibition for the treatment of specific types of cardiovascular disease. To date, the only ROCK inhibitor employed clinically in humans is fasudil, which has been used safely in Japan since 1995 for the treatment of cerebral vasospasm. Clinical trials, mostly focusing on the cardiovascular system, have uncovered beneficial effects of fasudil for additional indications. Intriguing recent findings also suggest significant potential for ROCK inhibitors in the production and implantation of stem cells for disease therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据